PATENT CLAIM ANALYSIS

Application Number: 15750318
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "482000"]

Abstract:
Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

Claim (Index 12):
The method according to  claim 6 , wherein the cancer is a drug-resistant cancer.

Metadata:
- Claim Count in Document: 48.0
- Percentile: 88.0
- Lexical Diversity: 1.52778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14770994', '14387735', '14147689', '12865620', '15002457']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7882108379375984
- 35 USC 102 Novelty (BERT): 0.5384888361702103
- Combined Prediction Score: 0.7632386377608595
- Mean Citation Score: 304.030938
- Max Citation Score: 382.53238
- Similarity Product: 212.5524736909533

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test